UAE Regulatory Alert: Exosome & PDRN Products
What manufacturers and brand owners should know about the UAE pathway for unauthorized Exosome and PDRN medical products.
Read More
Book 15 minutes ViaFarma Insights
Practical guidance for regulated healthcare markets.
Regulatory affairs, market access, coding and commercial readiness—explained clearly.Expanded from topics shared on our LinkedIn page
DHA Focuses on Regulatory Handling of Peptide Products in Dubai Healthcare Facilities
What healthcare facilities, manufacturers and international companies should review when handling peptide products in Dubai.
Read More
Five common mistakes in UAE product registration
How pathway, documentation, local partners and post-approval planning affect a successful launch.
Read More
UAE medical device registration in 2026
What manufacturers should prepare for EDE classification, representation, submission and lifecycle compliance.
Read More
Healthcare cybersecurity is part of patient safety
Why protecting health information is a clinical, operational and governance priority—not only an IT task.
Read More
Abu Dhabi HTA: demonstrating value beyond approval
Why clinical, economic and budget-impact evidence increasingly matters for reimbursement decisions.
Read More
Solving coding and insurance barriers across the Emirates
How early coding, payer and reimbursement planning can close the gap between approval and patient access.
Read MoreNeed advice on a specific pathway?
Book a focused 15-minute consultation.
These articles provide general information only. Requirements may change and should be confirmed for each product and authority.